Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
23 sept. 2014 09h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced an out-licensing
agreement for TGR-1202, a novel next generation PI3K-delta
inhibitor. TG...
Rhizen Pharmaceuticals S.A Announces a Scientific Presentation on the PI3K-Delta Inhibitor, TGR-1202, at the XV International Workshop on Chronic Lymphocytic Leukemia at Cologne, Germany
09 sept. 2013 09h04 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals announces a scientific poster
presentation on the PI3K-delta inhibitor, TGR-1202, by the Duke
University...